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1INTRODUCTION
The HIV/AIDS epidemic is a major global public health crisis with an
estimated   40 million adults and children living with HIV infection [1].  HIV
Associated  Neurocognitive Disorders (HAND)  is characterized by cognitive,
behavioral, and motor dysfunction and occurs in 10-15%  of HIV-
seropositive individuals with advanced infection [2] in the US .The frequency
of HAND is largely unknown in resource-limited countries, although
preliminary surveys suggest a relatively high frequency of cognitive
dysfunction [3].
 If a similar proportion were to be seen on a global scale, then HIV
dementia would be the most common cause of dementia worldwide in
patients under the age of 40 years. Despite the availability of HAART, HIV-
related neurological disorders continue to represent substantial personal,
economic and societal burdens. [4,5]
 Frequently a set of patients show subclinical neurocognitive
impairment, which does not fulfill the criteria for HIV Associated Dementia
proposed  by the American Academy of  Neurology (AAN). [6]
 These patients do not exhibit  recognizable functional restriction in
daily activities and may be missed in conventional screening and
Neuropsychological testing. But they progress to frank dementia eventually
2unless it is identified earlier and checked by effective Anti Retroviral
Therapy.
 Early recognition of subclinical neurocognitive impairment   is
essential to prevent the transformation to frank dementia which is associated
with significant morbidity and mortality. The diagnosis of neurocognitive
impairment is dependent upon a clinical history and a detailed
Neuropsychological testing which is time consuming, language and education
dependent, and often not available in developing countries. [7]
Continuous high level replication of  HIV virus leads to virus and
immune mediated killing of CD4 T lymphocytes , resulting in CD4 depletion.
As the disease progresses, CD4 count declines and this has been proved in
many studies.[8]
Evoked Response Potential (ERP) testing like P300 evaluation may
show abnormalities in patients with subclinical neurocognitive impairment [9]
and may help in identifying patients with subclinical impairment which has
therapeutic implications.
With this background, this study of, “ P300 evaluation in
asymptomatic HIV infected  patients” to explore subclinical
electrophysiological abnormalities was conducted at Institute of Neurology,
3Madras Medical College and Rajiv Gandhi Government General Hospital,
Chennai.
 Correlation of  CD 4 profile with P300 latency was also analyzed in
the  study    as  it  has  been   shown  earlier  that  CD4  count  has  an  inverse
correlation  with P 300 latency. [10]
4REVIEW OF LITERATURE
Decline in mental processes is a common complication of HIV
infection.
HIV-Associated Neurocognitive Disorders (HAND)
HIV can mimic the effects of other neurocognitive disorders. An
accurate diagnosis must differentiate from among a number of diseases that
present similar symptoms. Some conditions that share symptoms include:
depression, encephalitis, substance abuse, thyroid disorder, Alzheimer's,
Parkinson's, Huntington's, pick's, Creutzfeldt-Jacob, cerebrovascular disease.
Symptoms may include: delirium, memory impairment, apathy, social
withdrawal, psychosis, seizures, behavioral changes, disinhibition, tremors,
ataxia, repetitive movements, imbalance, hypertonia, visual impairment, etc.
The neurologic consequences of HIV were recognized early in the
epidemic. AIDS dementia complex (ADC) was the term used to collectively
describe the effects of HIV on the CNS. Today, the term ADC is a being
displaced by standards that focus more on how HIV is currently affecting
neurocognitive status and less on end stage disease.
Currently, highly active antiretroviral therapy (HAART) is still
effectively suppressing the life threatening opportunisitic infections which are
the hallmark of AIDS. HIV+ patients are living longer before their condition
5meets AIDS criteria. The incidence of the more severe form of neurocognitive
disorder, HIV-associated dementia (HAD), has also decreased but improved
testing and awareness has shown that HIV has a neurologic effect long before
a diagnosis of AIDS. Regardless of HAART, the neurocogitive effects of HIV
are still associated with the stage of HIV disease.
In 1991 the AIDS Task Force of the American Academy of Neurology
published definitions to guide the diagnosis of HIV associated neurocognitive
disorders  (HAND).  They  defined  two  levels  of  HAND:  HIV-associated
dementia (HAD) and minor cognitive motor disorder (MCMD).
In 2007, the National Institute of Mental Health and the National
Institute of Neurological Diseases and Stroke proposed an updated standard
for diagnosing HAND. The new proposed criteria creates an additional
category; HIV-associated asymptomatic neurocognitive impairment (ANI). It
also modifies the name and criteria for what was called MCMD to mild
cognitive disorder (MCD).
6Table - 1
Recent proposed diagnostic standards for HAND :
HIV-associated asymptomatic neurocognitive impairment (ANI)
diagnostic criteria
Cognitive impairment must be
attributable to HIV and no other
etiology, i.e:
? Dementia
? Delirium
? Depression
? CNS neoplasm
? CNS infection
? Cerebrovascular
disease
? Substance abuse etc.
Impairment involves at least two
cognitive domains and result in
neuropsychological testing
performance at least 1 SD below the
appropriate mean age/education norm.
? Information processing
speed
? Sensory/motor skills
? Short-term and long-
term memory
? Ability to learn new
skills and solve
problems
? Attention,
concentration, and
distractibility
? Logical and abstract
reasoning functions
? Ability to understand
and express language
? Visual-spatial
organization Visual-
motor coordination
? Planning, synthesizing
and organizing
abilities
7Table - 2
Mild Cognitive Disorder (MCD) diagnostic criteria (modified
for elucidation)
Cognitive impairment must be
attributable to HIV and no other
etiology, i.e:
? Dementia
? Delirium
? Depression
? CNS neoplasm
? CNS infection
? Cerebrovascular disease
? Substance abuse, etc
? Information processing
speed
? Sensory/motor skills
? Short-term and long-term
memory
? Ability to learn new skills
and solve problems
? Attention, concentration,
and distractibility
? Logical and abstract
reasoning functions
? Ability to understand and
express language
? Visual-spatial organization
Visual-motor coordination
? Planning, synthesizing and
organizing abilities
Patient or caregivers report
that cognitive deficit interferes with:
home making or social
activity,  Mental acuity, work
efficiency,
8HIV-associated dementia (HAD) diagnostic criteria
Cognitive impairment must
be attributable to HIV and no other
etiology, i.e:
? Delirium
? Depression
? CNS neoplasm
? CNS infection
? Cerebrovascular disease
? Substance abuse, etc.
Impairment involves at least
two cognitive domains and result in
neuropsychological testing at least 2
SD below the appropriate mean
age/education norm.
? Information processing
speed
? Short-term and long-term
memory
? Ability to learn new skills
and solve problems
? Attention, concentration,
and distractibility
? Logical and abstract
reasoning functions
? Ability to understand and
express language
? Visual-spatial organization
Visual-motor coordination
? Planning, synthesizing and
organizing abilities
Cognitive
impairment significantly interferes
with:
? work
? home life
? social activities
? ADL's
Cognitive impairment should
be validated by neuropsychological
testing, i.e.:
? Mini-mental state
examination (MMSE)
? Memorial Sloan-Kettering
(MSK) scale
? HIV dementia Scale (HDS)
Table - 3
9Although the specific symptoms vary from person to person, they may
be part of a single disorder known as AIDS dementia complex, or ADC.
Other names for ADC are HIV-associated dementia and HIV/AIDS
encephalopathy.
It is a metabolic encephalopathy induced by HIV infection and fueled
by immuneactivation of brain macrophages and  microglia.[11] These cells are
actively infected with HIV and secrete neurotoxins of both host and viral
origin.
Histopathologically, it is identified by the infiltration
of monocytes and macrophages into the central nervous system (CNS),
gliosis, pallor of myelin sheaths, abnormalities of dendritic processes
and neuronal loss.[11][12]
The essential features of ADC are disabling cognitive impairment
accompanied by motor dysfunction, speech problems and behavioral change.
Cognitive impairment is characterised by mental slowness, trouble
with memory and poor concentration.
Motor  symptoms  include  a  loss  of  fine  motor  control  leading  to
clumsiness, poor balance and tremors. Behavioral changes may
include apathy, lethargy and diminished emotional responses and spontaneity.
ADC typically occurs after years of HIV infection and is associated with low
CD4+ T cell levels and high plasma viral loads. [13]
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Common symptoms include decline in thinking, or “cognitive,”
functions such as memory, reasoning, judgment, concentration, and problem
solving.
? Other common symptoms are changes in personality and
behavior, speech problems, and motor (movement) problems such as
clumsiness and poor balance.
? When these symptoms are severe enough to interfere with
everyday activity, a diagnosis of dementia may be warranted.
AIDS dementia complex typically occurs as CD4+ count falls to less
than 200 cells/microliter. It may be the first sign of AIDS. With the advent of
highly active antiretroviral therapy (HAART), the frequency of ADC has
declined from 30-60% of people infected with HIV to less than 20%. HAART
may not only prevent or delay the onset of AIDS dementia complex in people
with HIV infection, it can also improve mental function in people who
already have ADC.
Dementia only exists when neurocognitive impairment in the patient is
severe enough to interfere markedly with day-to-day function. That is, the
patient is typically unable to work and may not be able to take care of him or
herself. Before this, the patient is said to have a mild neurocognitive disorder.
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Diagnostic criteria
Marked acquired impairment of at least two ability domains of
cognitive function (e.g. memory, attention): typically, the impairment is in
multiple domains, especially in learning, information processing and
concentration/attention. The cognitive impairment is ascertained by medical
history mental status examination or neuropsychological testing.
1. Cognitive impairments identified in 1. interfere markedly with
day-to-day functioning.
2. Cognitive impairments identified in 1. are present for at least
one month.
3. Cognitive impairments identified in 1. do not meet the criteria
for delirium, or if delirium is present, dementia was diagnosed when delirium
was not present.
4. No evidence of another, pre-existing aetiology that could
explain the dementia (e.g. another CNS infection, CNS neoplasm,
cerebrovascular disease, pre-existing neurological disease, severe substance
abuse compatible with CNS disorder.[14]
While the progression of dysfunction is variable, it is regarded as a
serious complication and, untreated, can progress to a fatal outcome.
Diagnosis is made by neurologists who carefully rule out alternative
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diagnoses. This routinely requires a careful neurological examination, brain
scans (MRI or CT scan) and a lumbar puncture to evaluate the cerebrospinal
fluid. No single test is available to confirm the diagnosis, but the constellation
of history, laboratory findings, and examination can reliably establish the
diagnosis when performed by experienced clinicians. The amount of virus in
the brain does not correlate well with the degree of dementia, suggesting that
secondary mechanisms are also important in the manifestation of ADC.
AIDS Dementia Complex (ADC) is not a true opportunistic infection.
It is one of the few conditions caused directly by HIV itself, but it is not quite
as simple as that because the central nervous system can be damaged by a
number of other causes:
? opportunistic infections - there are many
? Primary cerebral lymphoma or metastasis of other AIDS-related
cancers
? direct effects of HIV in the brain
? toxic effects of drug treatments
? malnutrition
Many researchers believe that HIV damages the vital brain
cells, neurons, indirectly. According to one theory, HIV either infects or
activates cells that nurture and maintain the brain, known
13
as macrophages and microglia. These cells then produce toxins that can set
off a series of reactions that instruct neurons to kill  themselves. The infected
macrophages and microglia also appear to produce additional
factors chemokines andcytokines - that can affect neurons as well as other
brain cells known as astrocytes. The affected astrocytes, which normally
nurture and protect neurons, also may now end up harming neurons. The HIV
virus protein gp120 inhibits the stem cells in the brain from producing new
nerve cells.[15]In the neuronal cells, the HIV gp120 induces mitochondrial-
death proteins like caspases which may influence the upregulation of the
death receptor Fas leading to apoptosis.[16] Researchers hope that new drugs
under investigation will interfere with the detrimental cycle and prevent
neuron death.
ADC stage characteristics
Stage 0 (Normal) Normal Mental and Motor Function
Stage 0.5 (Subclinical) Minimal symptoms of cognitive or motor
dysfunction characteristic of ADC, or mild signs (snout response, slowed
extremity movements), but without impairment of work or capacity to
perform activities of daily living (ADL). Gait and strength are normal.
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Stage 1 (Mild)
Evidence of functional intellectual or motor impairment characteristic
of ADC, but able to perform all but the more demanding aspects of work or
ADL. Can walk without assistance.
Stage 2 (Moderate)
Cannot work or maintain the more demanding aspects of daily life, but
able to perform basic activities of self care. Ambulatory, but may require a
single prop.
 Stage 3 (Severe)
 Major intellectual incapacity - cannot follow news or personal events,
cannot sustain complex conversation, considerable slowing of all output.
And/or motor disability - cannot walk unassisted, requiring walker or personal
support, usually with slowing and clumsiness of arms as well.
Stage 4 (End Stage)
Nearly vegetative. Intellectual and social comprehension and responses
are at a rudimentary level. Nearly or absolutely mute. Paraparetic
or paraplegic with fecal and urinary incontinence.
There is no “typical” course of the ailment. Sometimes it remains
relatively mild; other times it may be severe or progress rapidly. Some people
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experience only cognitive disturbances or mood shifts, while others struggle
with a combination of mental, motor and behavior changes. How much these
changes disrupt a person’s day-to-day life differs from one individual to the
next and from one stage of the disease to another.
In part because it varies so much from person to person. HIV
Associated Dementia (HAD) is one of the most poorly understood aspects of
HIV disease. However, since people coping with HIV often need to take
many medications on a complicated timetable, maintain a regular schedule of
doctors’ appointments, keep track of paperwork for insurance and other
benefits, and perform additional tasks that demand significant organizational
and cognitive skills, a diagnosis of HAD can present obstacles to their ability
to maintain control over their lives and their health, and a challenge to
caregivers, partners and others who want to help.
HIV is often accompanied by cognitive impairments which are
typically assessed through standard neurometric test batteries.[17,18] Early
detection of neuro- psychological impairment in HIV is important since more
sensitive measures of subclinical changes in cognitive impairments might lead
to earlier treatment that could reduce, minimize, or possibly reverse cognitive
deficits associated with infection. Previous studies however, have reported
discrepant results regarding the severity of cognitive decline associated with
the asymptomatic and symptomatic stages of HIV-infection. [19,20 ]
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These equivocal reports of the clinical stage in which cognitive deficits
are detected in HIV-infected individuals may be due to the fact that
neurological dysfunction was assessed by different methods.
Standardized neurometric tests have long been used in both clinical
and research applications for the assessment of cognitive function. [21]
These paper and pencil type neurometric tests continue to serve an
important role in non-invasive assessment of a variety of psychological
conditions in HIV patients. Though widely accepted and used in the field,
their ability to detect subclinical changes and degree of specificity of deficit is
somewhat limited.
 One promising addition to the standard neurometric approach is the
use of physiological measures which discriminate different levels of cognitive
impairment between and within certain clinical categories. The  event related
potentials (ERP) of the electroencephalogram (EEG) are associated with
subclinical changes in cognitive functioning in HIV-infected individuals.
Specifically, components of the ERPs that result in a longer P300 latency with
or without N1, P2, and N2 latency prolongation and/or smaller amplitude of
P300 waveforms, when compared to a control group, are shown to be related
to cognitive deficit. [22,23]
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Diagnosis:
Many factors can cause the same symptoms as HAD, so making a
correct diagnosis is a complex and challenging task. Depression, other
psychiatric disturbances, reactions to medication and nutritional deficiencies
can all lead to similar symptoms, as can infections common among people
with AIDS, including toxoplasmosis, lymphoma, progressive multifocal
leukoencephalopathy (PML) and cryptococcal meningitis.
An accurate diagnosis of HAD, therefore, requires a comprehensive
examination that generally includes a mental status test, a brain scan, and lab
tests on the cerebrospinal fluid (a fluid that bathes the brain and spinal cord),
which is obtained through a procedure known as a spinal tap or lumbar
puncture.
A mental status exam can help identify whether a person is suffering
memory loss, difficulties with concentration and other thinking processes,
mood swings and other symptom.
A structured demographic assessment, medical history, and
neurological examination. The neuropsychological testing battery covered six
domains including verbal memory (Rey Auditory Verbal Learning test),
constructional praxis (Rey Complex Figure Copy test), psychomotor
performance (Digit Symbol test, Trail Making test), motor speed (Grooved
Pegboard test), frontal systems (Verbal Fluency, Odd Man Out tests), and
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reaction time [California Computerized Assessment Package (CALCAP)] [24-
26]. An age and education adjusted z score was used to quantify performance
for each of the neuropsychological tests . Functional performance and
depression symptomatology also are assessed. These assessments are used to
assign a Memorial Sloan Kettering (MSK) dementia stage [27], by a consensus
conference including a neurologist (N.S.) and neuropsychologist.
The neuropsychological testing battery may include the World Health
Organization (WHO) University of California Los Angeles (UCLA) Verbal
Learning test for verbal memory [28]. This test is similar to the Rey Auditory
Verbal Learning test (RAVLT) in that it uses a list-learning task.
The Timed Gait and Grooved Pegboard tests were used to assess motor
performance. The Digit Symbol test [29] and the Color Trails test [30] were used
to assess psychomotor speed performance. The Color Trails 1 and 2 are
similar to the Trail Making test except that to minimize cultural bias, no
letters or written instructions are used. Both Color Trails 1 and 2 consist of
several numbered circles colored in pink or yellow; in Color Trails 1, each
number is represented by only one color, whereas in Color Trails 2, each
number is printed twice, once in pink and once in yellow. In Color Trails 1,
the participant is instructed to draw a line between the numbered circles one
after the other, following the number sequence. In Color Trails 2, the
participant must maintain the sequence of numbers and alternate between pink
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and yellow. Digit span forward and backward was used to assess attention.
The functional assessment included the Karnofsky Performance Scale [31].
These assessments were used to assign a MSK dementia stage of 0, 0.5, or ? 1
by a consensus conference. In addition, electrophysiological evaluation such
as ERP(P-300) evaluation may be helpful in detecting subtle neurocognitive
abnormalities which may not be picked up by conventional neurometric tests.
This physiological test and neurometric tests are complementary to each other
in evaluation of  neurocognitive disorders in HIV affected patients.
The healthcare provider will often ask that the test be repeated to
ensure accuracy. Initially these changes can be barely noticeable; it takes a
skilled clinician to pinpoint changes at the earliest phase of the condition. A
formal diagnosis requires that the behavior/memory changes be corroborated
by a third party.
CT and MRI brain scans can reveal whether someone has suffered
damage to brain tissue and can help rule out other possible causes of the
symptoms. And the cerebrospinal fluid of people with HAD frequently
contains high levels of HIV as well as greater amounts of certain proteins,
although such findings suggest rather than prove that someone is suffering
from the syndrome.
Because no single test definitively answers the question of whether
someone has HAD, the final diagnosis is made by weighing all the evidence
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together. Compounding the difficulty is the fact that HAD can sometimes
coexist with AIDS-related infections or other factors, and determining the
exact cause of each particular symptom can be virtually impossible. Time and
repeated measures are helpful in confirming a diagnosis.
Treatment:
Although there is no cure for HAD, AZT, an anti-HIV drug approved
by the Food and Drug Administration in the late 1980s, can help improve
cognitive functioning in people with HIV. While many drugs are not able to
penetrate the brain, AZT and some other antiretrovirals has been shown to
cross the blood-brain barrier, which is one reason why AZT may improve
symptoms of HAD. A major problem, however, is that although larger doses
of AZT apparently work best, people with HAD or advanced cases of AIDS
may be highly sensitive to the potentially toxic side effects of the drug.
There are several other anti-HIV drugs—d4T, abacavir, and
nevirapine, for example—that are known to cross the blood-brain barrier.
Some specialists believe that these drugs may also prove effective in treating
HAD, although the benefits have not been definitively proven. Much more
study on treating HAD is necessary before any firm conclusions can be
reached.
In addition to treating HAD itself, it is important to find ways to treat
the symptoms, when possible. Anti-depressants, anti-psychotics, and anti-
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anxiety drugs can help relieve some of the mental distress people with HAD
may experience. However, some of these medications may cause
complications when taken along with antiretroviral therapy or other drugs, so
caution is needed in choosing the best approach. Consultation with an AIDS-
knowledgeable psychiatrist is recommended.
ROLE OF COGNITIVE EVOKED POTENTIAL IN HAND
Long latency evoked potentials (ERP), are related to cognitive
processing and are referred to as cognitive evoked potentials, event-related
potential (ERP), P3, P300. Apart from Neuropsychological testing, P300
evaluation is found to be useful in detecting HIV associated Neurocognitive
disorders. More importantly, P300 evaluation has been found to be useful in
detecting early cognitive impairment in a proportion of neurologically
asymptomatic HIV patients, which may have huge impact in the management.
More effective therapy with Anti-Retroviral therapy can be introduced quite
early in the course, which will prevent the transformation into frank dementia.
COGNITIVE EVOKED POTENTIAL
Long latency evoked potentials (EPs) are related to cognitive
processing and are referred to as cognitive evoked potentials,  event-related
potential (ERP), P3, P300, and endogenous EP.  The event-related potentials
differ from short latency evoked potentials by the following characteristics:
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Endogenous stimuli elicit ERP, whereas short latency evoked
potentials are elicited by exogenous stimuli.
1. Endogenous evoked potentials require attention and patient’s
cooperation, whereas short latency evoked potentials in most instances can be
elicited without patient’s cooperation, during sleep and under anesthesia.
2. Endogenous evoked potentials have a longer latency, higher
amplitude, and lower frequency of waveform compared to short latency EPs.
3. Endogenous evoked potentials are not influenced by frequency
and intensity of stimuli as opposed to short latency EPs.
P300:
P300 is the most frequently investigated ERP appearing at about 300
ms  following  task-related  stimuli.  The  terms  P3  and  P300  ms  are  used
interchangeably.  P3 is a symmetrical wave maximum over the midline,
central and parietal regions with a latency varying between 250 ms and 600
ms depending on the stimulus and the subject parameters.
 P3 can be elicited by any stimulus, the most common being an
unexpected or infrequent stimulus (oddball paradigm). This involves
presentation of unexpected, infrequent stimuli randomly interspersed among
frequent stimuli.  The character of unexpected stimuli differs from the
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common stimuli in terms of frequency or intensity.  The unexpected stimulus
may even be the absence of stimuli in a train of regularly spaced stimuli [32].
Two factors, (i) stimulus infrequency or unexpectedness and (ii)
attention to task relevance operate independently. There is a suggestion that
unexpectedness of stimulus and attention to it produce different EPs [33].
Independence of task relevance in infrequent stimulus elicits a P3, which was
referred  by  squires  as  P3a.  This wave form occurs slightly earlier and has a
more frontal distribution than the parietal maximum P3b components wave,
which is best elicited by attending to a task relevant stimulus.  Probably the
routinely obtained P3 represents a sum of these components (P3a and P3b).  The
other long latency components, i.e., N1, P2, N2, and slow waves are clinically
less useful.
Subject
An acoustically and electrically shielded room is required for P3 study.
The subject is explained the procedure with emphasis on remaining awake
and alert during the test.  The procedure is done after cleaning the scalp. The
subject may comfortably sit or lie down supine in a couch with eyes fixed to
avoid blinking.  The subject is asked to mentally count the numbers of the
target stimuli or to respond to the target stimuli or to respond to the target
stimuli by raising the finger or pressing a button, which allows the assessment
of accuracy of responses.
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Electrode Placement:
After cleaning the scalp with antiseptics solution Surface recording
electrodes  are  placed  at  Fz,  Cz,  Pz,  and  are  referred  to  link  mastoid,  linked
ear, nose or noncephalic reference.  The ground electrode is placed at Fpz.
Additional electrodes may be placed to monitor eye movements, which may
be time locked to the target stimuli.  The electrode impedance is kept below
5k?.
Stimulus:
Any stimulus auditory, visual, olfactory, somatosensory  or pain can be
used for eliciting P3.   The  P3 elicited by different stimuli is fairly similar
though slight difference in latency and topography may be present.  Auditory
stimuli are most frequently used in clinical practice for eliciting P3.
The stimuli are delivered using oddball paradigm where two types of
stimuli:  target (infrequent) and nontarget (frequent) are used.  The target
stimuli comprise 15-20 % of total stimuli, which appear randomly.  The
patient is asked to count mentally or raise the finger or press a button in
response to target stimuli.
The sequence of presentation of target and non-target stimuli is
important.  If the target stimuli appear at the fixed interval then it does not
remain unexpected and influences the amplitude of P3.   It  is  therefore,
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important to use a random or pseudorandom sequence contains a random
sequence of target and nontarget with conditions on the stimuli sequence so
that no two-target stimuli appear consecutively.  A pseudorandom sequence is
preferred over random sequence because of the effect of local sequence
probability.
The stimulus intensity of 60-80 dB   is delivered binaurally at a rate of
1 Hz.
Machine Setup and Running the Test:
The low pass filter is kept between 30 Hz and 100 Hz and high pass
filter between 0.3 Hz and 1 Hz with sweep time of 1s.  The EEG is amplified
10,000 times and the evoked potential waveforms are computed separately for
all rare and frequent stimuli.
WAVEFORM  IDENTIFICATION AND MEASUREMENT
The positive and negative waveforms are designated as P and N,
respectively (P2 and P3) waves.  These are labeled by their average latency in
normal individuals, i.e., P3 appears around 300 ms after the stimulus.  Precise
measurement of P3 latency and amplitude is difficult because of its variable
morphology and broad configuration.  P3 is composed of two components:
P3a and P3b. Ideally, both the components should be measured although in
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clinical practice only P3 measurements are done. There are two ways of
measuring P3 latency.
1. Point of maximum P3 amplitude
2.  Intersectional extrapolation – the ascending and descending
limbs of P3 are extended to the point of intersection, which is measured as P3
latency.
P3 amplitude is measured from prestimulus base to-peak – to –peak
from N2 .  Generally P3 amplitude decreases as the latency increases. [34] The
normal values of different waveforms of cognitive evoked potential are given
below.
Normative data of cognitive evoked potential  ( U.K.Misra,Clinical
Neurophysiology)
Table - 4
Waveforms
Latency
( peak )
(mean ± SD) ms
Amplitude
(base-peak)
(mean ± SD) µv
Cz
      N1 102.0 ± 16.9 9.3 ± 3.5
      P2 172.1 ± 20.0 3.6 ± 2.5
      N2 232.1 ± 39.2 7.3 ± 4.1
      P3 346.9 ± 38.1 9.2 ± 5.0
Fz
     P3 346.5 ± 38.0 6.6 ± 3.6
Pz
    P3 346.2 ± 41.1 9.6 ± 3.8
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P-300 recording
FIGURE 1. Long-latency evoked potentials recorded from the vertex in two
subjects  of  similar  age,  one  of  whom  was  demented.  The  top  row  shows  the
response recorded from the demented subject.  The bottom row shows the response
recorded from the normal subject, The waveforms on the left are the responses to the
frequent tone and those on the right are to the rare tone. The latency and amplitude
of  the  N1  and  P2  components  are  similar  in  the  two  subjects,  but  the  later  event-
related components are small and delayed in the response from the demented
subject. ( Aminoff, Electrodiagnosis in Clinical Neurology )
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GENERATORS OF P3
The exact origin of P3 is still not known.  Different areas of brain such
as inferior parietal lobule, frontal lobe, hippocampus, medial temporal lobe,
insula, and other limbic structures have been reported to contribute to scalp
recorded P3.  Despite suggestion regarding the generation of P3 by medial
temporal lobe and hippocampus, later studies have disproved the role of
medial temporal lobe by demonstrating the presence of P3 in patients with
temporal lobectomy or bilateral hippocampal and temporal lobectomy or
bilateral hippocampal and temporal lobe lesions . Normal P3  , was also
recorded in a patient who had bilateral medial temporal lobe involvement
following herpes simplex encephalitis.
Recent studies employing fMRI and magnetoencephalography have
been utilized to study the generators of P3.  Combined ERP and fMRI study,
P3a was attributed to frontal area and insula, whereas P3b to parietal and
inferior temporal areas; thus pointing to the involvement of distinct attentional
subsystems in target and distracter processing .
In dementia, prolongation of P3 latency compared to normal has been
reported.  The frequency of abnormality has ranged between 30 % and
80%.[34]  P3 may be helpful in differentiating behavioral abnormalities in
dementia and those because of psychiatric disturbances. P3 is expected to be
normal in psychiatric patients as opposed to patients with dementia.
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There have been many studies with differing results on the role of P3 in
the diagnosis of dementia.  In the early stage of dementia, the P3 may be
normal or marginally altered, which undermines the value of P3 as  a  clinical
diagnostic test of dementia.  In a study on 27 demented patients whose Mini
Mental Scale Examination (MMSE) score was below 25; 80% patients had
prolonged P3 exceeding 2 Standard Error of Estimate (SEE) above age
latency regression time.  Moreover, there was no significant difference in
normal individuals and nondemented controls .
 In 18 demented patients with MMSE  score below 20 and 7 with
psychogenic illness, 56% of demented patients and none of psychogenic
patients had prolonged P3 latency exceeding mean by 2 SEE in another study,
35 senile-depressed patients were compared with 39 normal subjects.  Mean
latency of P2 and P3 were shorter in senile-depressed compared to control,
but in Alzheimer’s disease N2 and P3 were prolonged.[35]
Degree of dementia has been correlated with P3 in several studies.
Blessed Dementia Scale Score, a marker of degree of dementia and delta
activity in EEG were not significantly related to P3 latency. Sequential studies
of P3 in dementia have revealed increase in P3 latency with disease
progression [36].  Patients with infarctions without dementia have normal P3
latencies.  The sensitivity of P3 in vascular dementia is about 50 %, which is
similar to Alzheimer’s disease.
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HIV  Infection
Patients with HIV infection often complain of cognitive disturbance,
which may be due to AIDS dementia complex, HIV- associated
encephalopathy or due to CNS opportunistic infections.  In asymptomatic
HIV patients there is a low frequency of P3 abnormalities,  which may range
from 0% to 30 %.[37,38] In symptomatic HIV patients (CDC stage II-IV), N2,
P3 complex abnormalities occur in 33-80% patients.  These abnormalities
include latency prolongation, reduction of amplitude, or loss of waveforms.
The effect of antiretroviral therapy has been monitored by P3.
 In a longitudinal study, change in latency and amplitude was more
frequent in HAART therapy group compared to mono, duo therapy or control
group.  This study highlights the important role of HAART  therapy in
improving cognition in HIV patients.  The P3 abnormality inversely
correlated with CD4 count. [39]
VARIABLES AFFECTING P3
A number of variables may affect P3 latency and amplitude, hence they
require careful attention to avoid misinterpretation.
1. AGE
The P3 latency increases with increasing age.  There is an increase in
mean latency by about 1-1.5 ms/year after the age of 20 years. There are
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conflicting reports on the influence of age on the amplitude of P3, however
probably the amplitude decreases after the age of 80 years
2. ATTENTION
Decrease in alertness is associated with reduction in amplitude .
Drowsiness or inattention decreases P3 amplitude or may even obliterate it.
However, P3 can be recorded in stage II sleep but disappears in slow wave
sleep.  P3 amplitude increases with correctly recognized stimuli compared to
incorrect ones.
3. TASK
The latency increases as the discrimination of task becomes harder. [40]
If the subject is asked to attend to target stimulus it results in higher amplitude
P3 compared to a situation in which such instruction was not given.
Since 1991, investigators have used the term Minor Cognitive Motor
Disorder (MCMD) to describe neurological and neuropsychological
symptoms and signs which are not severe enough to meet criteria for frank
dementia. It is estimated that 20-30% of individuals with advanced HIV
infection (CD4 cell counts < 200 mm3) may show evidence of some
impairment of cognitive or motor performance. In recent years the
significance of these "minor" abnormalities has become better understood;
however, it is still uncertain whether a "predementia syndrome" can be clearly
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characterized, and if it can, whether aggressive early treatment can forestall
the development of frank dementia.
The incidence and prevalence of MCMD are poorly understood. This is
primarily because diagnostic criteria are relatively new, and insufficient
epidemiological research data only are available. The rate of MCMD is low in
medically asymptomatic HIV infection (5%) but increases to about 25%
during the symptomatic phases of the disease. In contrast, frank HIV
dementia was detected in 0.8% of medically asymptomatic individuals, in
2.6% of symptomatic, and 7.0% of those with clinically-defined AIDS.
MCMD may be associated with increased mortality, because of
behavioral disturbances and poor adherence to anti retroviral therapy  and this
increased risk of death applies not only to those who become frankly
demented. Mayeux and colleagues, for example, reported earlier death in
those who were neuropsychologically impaired but not demented. In addition
to its possible prognostic significance, MCMD also has a clear impact on
function. For example, in a cohort of individuals with advanced HIV
infection, functional performance was significantly worse among those with
MCMD than among HIV-infected individuals without neuropsychological
impairment.
MCMD may not necessarily progress to frank dementia. In fact, some
individuals with MCMD may improve when retested, possibly indicating
some reversibility in the neurologic dysfunction. Why some people improve
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over time remains an open question. While the most obvious answer may be
"practice effect" and other sources of error in neuropsychological
measurement, another possibility is that the mildest form of brain disorder
associated with HIV might actually have a fluctuating course, somewhat akin
to what is found in demyelinating disorders. It is clear now that even during
the lengthy asymptomatic phase of HIV infection, bursts of viral replication
occur, and there is no true viral latency. These "viral bursts" might be
accompanied by further brain seeding influencing neuro-psychological
performance.
In summary, although information on the "real life" implications of
HIV-associated MCMD remains fragmentary, the available data indicate that
such impairments may be associated with reduced work efficiency, greater
likelihood of development of frank dementia, and earlier mortality.
 The implication is that screening of individuals with advanced HIV
infection, who are at risk for HIV dementia and MCMD, is probably
warranted. Simple bedside tests such as the HIV Dementia Scale (included
below), which was developed in the Moore Clinic for the early detection of
dementia, are particularly useful.
 In general, a score of 10 or less is suggestive of HIV associated
cognitive impairment or dementia and would warrant additional neurologic
consultation.
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In this setting, ERP testing such as P300 evaluation gains importance
as it may reveal abnormalities in the form of prolongation of P300 latency
much before overt dementia sets in.
HIV Dementia Scale  (devised by Power.C )
Max Score Score Memory-Registration Give  four  words  to  recall
(dog, hat, green, peach) - 1 second to say each. Then
ask the patient all 4 after you have said them.)
4 ( ) Attention  Anti-saccadic eye movements: 20
(twenty) commands. ____ errors of 20 trials.
less than or equal to 3 errors = 4; 4 errors = 3; 5
errors = 2; 6 errors = 1; > 6 errors = 0)
6 ( ) Psychomotor Speed Ask patient to write the
alphabet in upper case letters horizontally across the
page (use back of this form) and record time: ____
seconds.
less than or equal to 21 sec = 6; 21.1 - 24 sec = 5;
24.1 - 27 sec = 4; 27.1 - 30 sec = 3; 30.1 - 33 sec = 2;
33.1 - 36 sec = 1; > 36 sec = 0)
4 ( ) Memory - Recall Ask for 4 words from Registration
above. Give 1 point for each correct. For words not
recalled, prompt with a "semantic" clue, as follows:
animal (dog); piece of clothing (hat), color (green),
fruit (peach). Give 1/2 point for each correct after
prompting.
2 ( ) Construction Copy the cube below; record time:
____ seconds.
(< 25 sec = 2; 25 - 35 sec = 1; > 35 sec = 0)
Total Score: ____/16
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AIM OF THE STUDY
1. To evaluate P-300, an endogenous long latency evoked response
potential (ERP) in asymptomatic HIV patients without apparent,
clinical neurocognitive disturbances and to correlate it with age
matched healthy controls to study subclinical abnormalities.
2. To study HIV Dementia Scale (HDS) score in those neurologically
asymptomatic  HIV infected patients and  to correlate it with P300
abnormalities .
3. To study CD4 profile in those neurologically asymptomatic HIV
patients and to correlate it with electrophysiological findings.
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MATERIALS AND METHODS
 In  this  cross  sectional  study,   50  HIV  patients,  who  were
neurologically asymptomatic,  attending Rajiv Gandhi Government General
Hospital, ART clinic and Medicine OPD , and 60 age matched healthy
controls were enrolled from January 2009 to March 2011.  An informed
consent was obtained prior to the study.
Detailed history was taken , and meticulous neurological examination
was done to rule out clinical  neurocognitive disturbances. Those patients who
were asymptomatic after history and examination  were included in the study
and those with disturbances were excluded.
Then the subjects were asked to perform the Moore clinic HIV
Dementia Scale testing, (maximum score- 16) recommended by American
Academy of Neurology. Patients who scored less than or equal to10 were
excluded from the study and those who scored more than 10 alone were taken
for the study.
In the patients who scored more than 10, the maximum score on the
HIV Dementia scale was noted.( possible  score- 10.5 to 16 )
After the HIV Dementia scale testing, P-300 evaluation was done for
those patients after obtaining due consent.  P-300 analysis was done using
auditory “ODDBALL PARADIGM” technique. The parameters considered
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were  N1 latency, P2 latency, N2 latency, P3 latency and N2-P3 amplitude.
Recording over Cz was taken into consideration.
HIV Dementia scale score was correlated with P-300 latency to
demonstrate any statistically significant correlation.
Then the other parameters, N1, P2, N2, P3 latencies and P3 amplitude
were analyzed statistically in both the patient group and the control group to
find out abnormal values,  in the form of prolongation of latency of N1, P2,
N2, P3 waves or reduction in the P3 amplitude and eventually identifying
patients with abnormal P3 findings, who have subclinical neurocognitive
impairment , revealed by neurophysiological methods.
         And also CD4 count was done for the patient group which was
then correlated with P-300 latency to look for any statistically significant
correlation between these two parameters.
Inclusion criteria:
1.  HIV positive patients with or without ART therapy, irrespective of
duration of illness.
2. HIV positive patients with or without Anti Tuberculous Treatment
3. HIV positive patients with or without prophylaxis for opportunistic
infections.
 4. Age 15 years and above were included.
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Exclusion criteria:
1. Patients in moribund state.
2. Patients with apparent features of  Dementia
3. Patients with clinical neurological deficits.
4. Patients with space occupying lesions, opportunistic infections
in brain.
CD4 T cell count, complete hemogram, renal and liver function tests
and neuroimaging   ( CT-Brain  or MRI Brain as required ) were done.
After obtaining the results data analysis was done using SPSS
statistical package.
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RESULTS AND DATA ANALYSIS
 50 HIV positive asymptomatic patients and 60 age matched controls
were enrolled.
In the patients group 34   (68%   ) were males and 16 (32% ) were
females.
In the control group 36   (60%   ) were males and 24 (40%) were
females.
Sex Distribution:
Table - 5
Sex Patients Controls
Male 34 (68%) 36 (60%)
Female 16 ( 32%) 24 (40%)
 In the patients group,  35 ( 70%  ) were in the 30-40 age group.
   4   (  8%  ) were  in the <30 age group.
  11  (  22% ) were  in the >40 age group.
 In the control group,  38 subjects  ( 63.4%  ) were in the 30-40 age
group.
  5  subjects ( 8.3 %  ) were  in the <30 age group.
 17 subjects (28.3 % ) were  in the >40 age group.
SEX  DISTRIBUTION
FIGURE 2  : PATIENTS
FIGURE 3 : CONTROLS
AGE  DISTRIBUTION
FIGURE 4  : PATIENTS
FIGURE 5 : CONTROLS
PATIENTS VS CONTROLS
FIGURE 6 : P 300 ABNORMALITIES
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AGE DISTRIBUTION:
Table – 6
Age group, in years Patients Controls
<30 4(8%) 5(8.3%)
30-40 35(70%) 38(63.4%)
>40 11(22%) 17(28.3%)
Pearson Correlation analysis was done to demonstrate  statistically
significant correlation between variables; and ‘T’ test was done to
demonstrate significance.
SUBJECTS = HIV
Correlation  (a)  Pearson Correlation
Table - 7
DUR
ILL YRS
HIV DS
SCORE
P3,  N1  L
ms P2 L ms N2 L ms P3 L ms
P-3,amp
micV CD4+
DUR ILL
YRS
1 -.546(**) .637(**) .527(**) .497(**) .658(**) -.471(**) -.416(**)
HIV DS
SCORE
-.546(**) 1 -.727(**) -.565(**) -.571(**) -.633(**) .659(**) .528(**)
P3, N1 L ms .637(**) -.727(**) 1 .620(**) .680(**) .746(**) -.715(**) -.649(**)
P2 L ms .527(**) -.565(**) .620(**) 1 .641(**) .758(**) -.518(**) -.557(**)
N2 L ms .497(**) -.571(**) .680(**) .641(**) 1 .793(**) -.759(**) -.721(**)
P3 L ms .658(**) -.633(**) .746(**) .758(**) .793(**) 1 -.771(**) -.747(**)
tP-3,AM
micV
-.471(**) .659(**) -.715(**) -.518(**) -.759(**) -.771(**) 1 .716(**)
CD4+ -.416(**) .528(**) -.649(**) -.557(**) -.721(**) -.747(**) .716(**) 1
**  Correlation is significant at the 0.01 level (2-tailed).
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SUBJECTS = Control
                                   (Correlations (b)  Pearson Correlation
Table - 8
HIV DS
SCORE P3, N1 L ms P2 L ms N2 L ms P3 L ms
P-3,AM
micV
HIV DS
SCORE
1 -.121 -.019 -.234 -.224 .113
P3, N1 L ms -.121 1 .278(*) .748(**) .771(**) -.570(**)
P2 L ms -.019 .278(*) 1 .291(*) .275(*) -.244
N2 L ms -.234 .748(**) .291(*) 1 .594(**) -.498(**)
P3 L ms -.224 .771(**) .275(*) .594(**) 1 -.658(**)
P-3,AM micV .113 -.570(**) -.244 -.498(**) -.658(**) 1
*  Correlation is significant at the 0.05 level (2-tailed).
**  Correlation is significant at the 0.01 level (2-tailed).
a  Cannot be computed because at least one of the variables is constant.
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T- tests were significant ( P < 0.05 )  for P3 latency in all age groups.
T-Test
AGE = <30 years
Table - 9
SUBJECTS N Mean
Std.
Deviation
Std. Error
Mean
‘t’ Sig
HIV DS
SCORE
HIV
4 14.63 .479 .239 .610
NS
Control 6 14.92 .861 .352
P3, N1 L ms HIV 4 94.8000 4.33590 2.16795 .507 NS
Control 6 97.0000 7.81665 3.19113
P2 L ms HIV 4 169.8000 7.47975 3.73988 1.183 NS
Control 6 176.3333 9.14367 3.73289
N2 L ms HIV 4 218.6000 23.68347 11.84173 .997 NS
Control 6 233.8000 23.56845 9.62178
P3 L ms HIV 4 307.6000 3.55903 1.77951 2.864 p<0.01
Control 6 320.4167 8.32356 3.39808
P3,AM micV HIV 4 9.6500 .50000 .25000 1.480 NS
Control 6 11.1833 1.99240 .81339
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AGE =30-40 years  `T' Test for Significance
Table - 10
SUBJECTS N Mean
Std.
Deviation
Std.
Error
Mean
‘t’ Sig
HIV DS
SCORE
HIV
35 13.47 1.218 .206 3.956
p<0.01
Control 36 14.58 1.150 .192
 N1 L ms HIV 35 105.2611 17.31848 2.92736 2.344 p<0.05
Control 36 97.5861 9.15155 1.52526
P2 L ms HIV 35 174.7789 16.82438 2.84384 .714 NS
Control 36 172.5222 8.64969 1.44162
N2 L ms HIV 35 234.9009 39.36446 6.65381 .052 NS
Control 36 234.4806 27.38022 4.56337
P3 L ms HIV 35 337.9666 44.04266 7.44457 2.423 P<0.05
Control 36 323.3750 14.20783 2.36797
P3,AM
micV
HIV
35 6.8740 2.50880 .42406 7.031
p<0.01
Control 36 10.4194 1.66782 .27797
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AGE >40 years   `T' Test for Significance
Table - 11
SUBJECTS N Mean
Std.
Deviation
Std. Error
Mean
‘t’ Sig
HIV DS
SCORE
HIV
11 12.59 .861 .260 4.299
p<0.01
Control 18 13.92 .772 .182
P3,  N1  L
ms
HIV
11 123.0s455 15.16999 4.57393 3.344
p<0.01
Control 18 104.7056 13.81033 3.25513
P2 L ms HIV 11 180.8636 21.45499 6.46892 1.041 NS
Control 18 174.2444 12.93210 3.04812
N2 L ms HIV 11 265.8273 30.64947 9.24116 1.302 NS
Control 18 252.1500 25.37160 5.98014
P3 L ms HIV 11 374.0636 55.85177 16.83994 2.881 p<0.01
Control 18 332.5444 20.42940 4.81526
P3,AM
micV
HIV
11 5.0909 1.48893 .44893 6.220
p<0.01
Control 18 9.2722 1.89638 .44698
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1.Duration of illness was correlated with HIV dementia score.  There
was a significant inverse correlation between these two variables. There was a
significant inverse correlation between those two variables. As the duration of
disease increased, the HIV dementia scale score decreased.[ -.536(**) ].
2. Duration of disease also had inverse correlation with CD4 count
[-.416(**)]
3. Duration of disease also had inverse correlation with P3 amplitude
[-.471(**)].
 4. Duration of disease  had direct correlation with N1[.637(**)],
P2[.527(**)],  N2[.497(**)],P3[.658(**)] latencies. As the disease progressed, decline
in CD4 count and P3 amplitude was noted , while N1, P2, N2 and P3 latencies
prolonged.
HIV dementia scale score was correlated with variables:
HDS score was directly correlated with CD4 count.[ .528(**)] in patient
group. Those patients with high HDS score had increased CD4 count while
there was no correlation between the two variables in the control group.
 HDS score was  inversely correlated with N1, P2, N2 and P3 latencies
and directly correlated with P3 amplitude in the patient group while no such
correlation existed in the control group.
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P3[-.747(**)], N2 [-.721(**)], P2[-.557(**)] , N1[-.649(**)] latencies
had an inverse correlation with CD4 count. As the count decreased, the
latencies of the positive and negative waves also prolonged. Reduction in P3
amplitude was noted with decreasing CD4 count. We had not done CD4 count
in control group and  such correlations  could not be derived.
DURATION OF ILLNESS IN YEARS IN HIV PATIENTS
Table - 12
DUR ILL YRS SUBJECTS Total
HIV
1 N 5 5
% 10.0% 10.0%
2 N 6 6
% 12.0% 12.0%
3 N 8 8
% 16.0% 16.0%
4 N 11 11
% 22.0% 22.0%
5 N 8 8
% 16.0% 16.0%
6 N 6 6
% 12.0% 12.0%
7 N 3 3
% 6.0% 6.0%
8 N 3 3
% 6.0% 6.0%
Total N 50 50
% 100.0% 100.0%
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Minimum duration of illness was one year and maximum duration was
eight years.
Of the HIV-infected patients, the percentage of patients who showed
an abnormal latency of the P300-components of  ERPs exceeding the mean
value + 2 SD of ERP latencies from age-matched healthy subjects were noted.
Standard deviation of P3 variables for the different a
ge groups
Table - 13
AGE P3, N1 L ms P2 L ms N2 L ms P3 L ms
P-3,AM
micV
<30 Mean 97.0000 176.3333 233.8000 320.4167 11.1833
Std.
Deviation
7.81665 9.14367 23.56845 8.32356 1.99240
Mean +
2SD 112.63 194.62 280.94 337.06 15.17
30-40 Mean 97.5861 172.5222 234.4806 323.3750 10.4194
Std.
Deviation
9.15155 8.64969 27.38022 14.20783 1.66782
Mean +
2SD 115.89 189.82 289.24 351.79 13.76
>40 Mean 104.7056 174.2444 252.1500 332.5444 9.2722
Std.
Deviation
13.81033 12.93210 25.37160 20.42940 1.89638
Mean +
2SD 132.33 200.11 302.89 373.40 13.06
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a  SUBJECTS = Control
age 1=<30 years , age2=30-40 years,  age 3=  > 40 years
In the patient group 12 patients (24%) had abnormally prolonged N1
latency values ( > 2 SD ),  while only 3 (5%) had abnormal values  in the
control group.
The mean, SD, mean+2SD, values of N1 for age groups of
patients given below
Table - 14
<30 Mean 97.0000
SD 7.81665
Mean + 2SD 112.63
30-40 Mean 97.5861
SD 9.15155
Mean + 2SD 115.89
>40 Mean 104.7056
SD 13.81033
Mean + 2SD 132.33
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Table - 15
N1 latency              patients vs controls
SUBJECTS Total
HIV Control
N1 latency < 2SD N 38 57 95
% 76.0% 95.0% 86.4%
>2SD N 12 3 15
% 24.0% 5.0% 13.6%
Total N 50 60 110
% 100.0% 100.0% 100.0%
In the patient group, 9 (18%) patients had abnormally prolonged P2
values  ( >2 SD), whereas only one (1.7%) patient had abnormal value.
The mean, SD, mean+2SD, values of P2Latency for Patients age groups
given below.
Table - 16
AGE P2 L ms
<30 Mean 176.3333
SD 9.14367
Mean + 2SD 194.62
30-40 Mean 172.5222
SD 8.64969
Mean + 2SD 189.82
>40 Mean 174.2444
SD 12.93210
Mean + 2SD 200.11
50
Table - 17
P2 Latency                  patients vs controls
SUBJECTS
TotalHIV Control
P2 latency < 2SD N 41 59 100
% 82.0% 98.3% 90.9%
>2SD N 9 1 10
% 18.0% 1.7% 9.1%
Total N 50 60 110
% 100.0% 100.0% 100.0%
In the patient group, 5 (10%)  patients had abnormally prolonged N2
values (>2 SD) while, in the control group, only one (1.7%) had
abnormalvalue.
The mean, SD, mean+2SD, values of N2Latency for patients
Table - 18
AGE N2 L ms
<30 Mean 233.8000
SD 23.56845
Mean + 2SD 280.94
30-40 Mean 234.4806
SD 27.38022
Mean + 2SD 289.24
>40 Mean 252.1500
SD 25.37160
Mean + 2SD 302.89
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Table - 19
N2 latency                patients vs controls
SUBJECTS
TotalHIV Control
N2 latency < 2SD N 45 59 104
% 90.0% 98.3% 94.5%
>2SD N 5 1 6
% 10.0% 1.7% 5.5%
Total N 50 60 110
% 100.0% 100.0% 100.0%
In the patient group, 13 patients had abnormally prolonged P3 latency
values( >2 SD), whereas only one patient had abnormal value.
The mean, SD, mean+2SD, values of P3 Latency for age groups given
below:
Table - 20
AGE P3 L ms
<30 Mean 320.4167
SD 8.32356
Mean + 2SD 337.06
30-40 Mean 323.3750
SD 14.20783
Mean + 2SD 351.79
>40 Mean 332.5444
SD 20.42940
Mean + 2SD 373.40
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Table – 21
P3Latency            patients vs controls
SUBJECTS Total
HIV Control
P3 latency < 2SD N 37 59 96
% 74.0% 98.3% 87.3%
>2SD N 13 1 14
% 26.0% 1.7% 12.7%
Total N 50 60 110
% 100.0% 100.0% 100.0%
In the patient category, no patient had a P3 amplitude value > 2 SD, while in
the control group, one person (1.7%) had an abnormal value.
The mean, SD, mean+2SD, values of P3Amplitude for age groups given
below:
Table - 22
AGE P-3,amp micV
<30 Mean 11.1833
SD 1.99240
Mean + 2SD 15.17
30-40 Mean 10.4194
SD 1.66782
Mean + 2SD 13.76
>40 Mean 9.2722
SD 1.89638
Mean + 2SD 13.06
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Table - 23
P3  Amplitude             patients vs controls
SUBJECTS Total
HIV Control
P3 Amplitude < 2SD N 50 59 109
% 100.0% 98.3% 99.1%
>2SD N 0 1 1
% 0% 1.7% .9%
Total N 50 60 110
% 100.0% 100.0% 100.0%
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DISCUSSION
HIV Associated Neurocognitive Impairment is a less recognized entity,
in HIV affected patients, though it is associated with considerable morbidity
and mortality, especially in developing countries. This is probably due to
behavioral disturbances and poor adherence to drug therapy.
Asymptomatic patients, may not exhibit overt restriction in day to day
functioning. So these patients do not seek medical attention and as a result
frequently progress to frank dementia.
Even Neuropsychological screening tests may not show features of
dementia. Under such circumstances, P300 evaluation gains grounds as an
important tool to demonstrate subclinical neurocognitive abnormalities ,
which will help in early institution of effective Anti-Retroviral Therapy to
prevent frank dementia.
In this study, P-300 abnormalities were noted in a proportion of
neurologically asymptomatic HIV patients. Abnormal latency prolongation
of both  early and late components of P300 was noted in those patients.
24% (12 patients) had abnormal N1 latency values ( > 2 SD )
18% (9 patients) had abnormal P2 values. (>2 SD)
10% ( 5 patients) had abnormal N2 values. (>2 SD)
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26% (13 patients) had abnormal P3 values.( >2 SD).
But the P3recorded did not show statistically significant decreased
amplitude in patients.
In this study, P3 latency was found to be prolonged in 26% of patients,
who were clinically asymptomatic as evidenced by more than 10 score in the
HIV dementia scale.
This finding was concordant with other studies.
Goodin DS, Aminoff MJ, in their study, “ Long latency event-related
potentials in patients infected with human immunodeficiency virus ”
observed,    in patients infected with human immunodeficiency virus (HIV) , a
proportion of  neurologically asymptomatic patients showed P3 latency
prolongation abnormalities .[37]
As in other subcortical dementias, patients with the HIV Associated
Neurocognitive Disorders had a prolongation of the early components of the
ERP, particularly the NI component, in addition to the prolongation of later
N2 and P3 components that occurs in other dementing disorders.
Importantly, Bungener and colleagues have confirmed these general
findings.[38] In addition, almost one-third of the asymptomatic patients
infected by HIV have ERP changes similar to those with overt dementia,
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which suggests that these patients may be at particular risk for cognitive
difficulties developing in the future.
Thus,  it  may  be  that  the  recording  of  ERPs  will  permit  early
recognition of HIV encephalopathy and thereby help to identify patients with
a poor prognosis or in need of more aggressive management.
Similarly, this study also showed that  in addition to the abnormalities
in the  cortical components of   P3,( N2,  P3 latency prolongation), N1 and P2
subcortical components also showed  latency prolongation,  reiterating the
point that HIV dementia is basically a subcortical variety. P3 latency
prolongation was noted in 26% of asymptomatic patients.
 But this study failed to show a statistically significant reduction in P3
amplitude in HIV infected subjects.
               Another study done by Jaime L. Tartar et al, pointed out that
a physiological measure of the EEG, the P3 component of the auditory ERP,
is an early indicator of cognitive decline in HIV-persons. Differences in P3
amplitude measures suggest that the available amount of attentional resources
are reduced in HIV infection and the P3 latency measures indicate that speed
of processing is compromised as well.
The present finding that otherwise asymptomatic patients display
cognitive impairments is suggestive that traditional neurometric tests might
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not be sensitive to the processes affected by early cognitive impairments.
Because HIV invades the CNS early in the course of the disease physiological
methods of assessing cognitive impairments may be of great importance for
the early diagnosis and treatment.
In another study, G. Arendt et al, [41] found that  N2, P3 latency
prolongations and P3 amplitude reduction were proportionate to degree of
dementia. Clinical bradykinetic symptoms and time-dependent psychometric
abilities correlated with N2 and P3 latency prolongations.
In yet another study, Gil R et al [42] observed endogenous event-related
potentials (and especially the P300 component) have delayed latencies
relative to normal controls in patients with dementias of diverse aetiologies.
Moreover, the subcortical varieties of dementia tend to affect also the early-
stage N1 and P2 components whereas both types of dementias affect the later-
stage N2 and P3 components. Several studies have shown that endogenous,
but also early, components of long latency auditory evoked potentials are
prolonged in latency in HIV-demented patients. However, these changes may
also  be  present  in  class  II  and  III  patients  and  may  permit  the  early
recognition of HIV encephalopathy.
In another study,  Polich  J,  et  al [43] found that P300 amplitude was
smaller, and latency was marginally longer for the HIV patients compared to
control subjects.
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P300 latency correlated positively with increases in the patient HIV viral load.
P300 group differences were consistent with declines in cognitive capability,
and P300 latency increased with increased viral load. HIV infection
negatively affected central nervous system function as measured by cognitive
ERPs in a manner that suggests decreased arousal and increased fatigue in
HIV patients.
Bahman Jabbari et al[44] performed Event Related potentials (ERPs)
along with neurological and neuropsychological evaluation, in 73
neurologically asymptomatic HIV infected subjects. The results were
compared with 50 age- and sex-matched controls. Event-related auditory
evoked potentials were performed in 39 subjects. They were abnormal in 5
subjects initially (12%) and in 6 subjects (15%) by the last examination and
more commonly in advanced stages of the illness with lower T4 counts. This
data shows the evolution and association of electrophysiological
abnormalities in early HIV infection and suggests a predictive value for ERP
in HIV infected asymptomatic individuals.
HIV dementia scale (HDS) score done for both patients group and control
group showed a  negative correlation between  HDS score and duration of
illness. As the duration of illness increased, a decline in the HDS score was
noted
But this sort of correlation could not be observed in the control group.
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Duration of illness had a direct correlation with N1, P2, N2, P3
latencies and inverse correlation with P3 amplitude. This is probably due to
the impact of HIV proliferation on the brain tissue.
There were correlations between HDS score and N1, P2, N2, P3
latencies in the patient group.  These latencies prolonged with declining score
in the HDS scale while it did not show any such correlation in the control
group.
P3 amplitude had a direct correlation with HDS score and patients with
high HDS score had proportionately large P3 amplitude. Some of the patients
with high HDS score had abnormal  P3 latency prolongation .
In this study, Pearson correlation analysis showed an inverse
correlation between CD4 count and P3 latency.  Patients with low CD4 cell
count had increased P3 latency values. This finding had been already
observed in the study done by Hussted et al, in 2002 who demonstrated  P300
abnormalities. In particular, P3 latency was inversely correlated with CD4
count, patients with low CD4 count had abnormal prolongation of P3
latency. [10]
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CONCLUSION
1. P-300 evaluation is an useful neurophysiological tool in
detecting subclinical neurocognitive impairment in a proportion of
asymptomatic HIV positive patients.
2.  Abnormal P3 latency prolongation was noted in 26% of
asymptomatic HIV patients in the study, which is  an indicator of subclinical
cognitive impairment.
3. In addition to P3 latency prolongation, the early subcortical N1,
P2, and N2 latencies were also prolonged in a proportion of patients,
reiterating the point that HIV dementia is basically a subcortical variety.
4. Early detection of subclinical neurocognitive impairment will
help in  intensifying Anti Retroviral Therapy which may modify or halt the
progression  of dementia in HIV  patients.
5. P-300, neurophysiological testing may be complementary to
neuropsychological screening tests, like HIV dementia scale,  as patients who
failed to show significant abnormalities in  HDS score had abnormalities
during P-300 evaluation.
6. CD4 cell count is inversely correlated with P-300 latency.
However, this is a small study and large scale studies need to be done to
confirm this observation.
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PROFORMA
  Name                                                      Age                            Sex                        Education
  Address
 Occupation
OP  no             MIN  no                                 ART no                               D.O.R:
Duration of illness
Initial presentation
Date of diagnosis                                             spouse affected: Y/N
CLINICAL FEATURES:
 MMSE score:
 HMF disturbances
Executive function:   Y/N
Apathy Y/N
memory :  Y/N, (  working,    recent,   remote)
Language:  motor/ sensory
reading/   writing/    copying
dysarthria:Y/N
apraxia
Ideational Y/N                                                      Ideomotor Y/N
Dressing Y/N                                                         Constructional  Y/N
R/L Confusion   Y/N
hemineglect :Y/ N
Visuospatial disorientation; Y/N,
Delusion/hallucination:  Y/N
Hemianopia/quadrantanopia: Y/ N
Cranial neuropathy: if any
Spinomotor:
Weakness:
Wasting
Ataxia :          Truncal/                                                   Appendicular:  R  /L/  Bilateral
Involuntary movements: if any
Sensory: Y/N,                                       Type:                           Romberg : P/N
Gait:
Signs of meningeal irritation:  Y/N
Peripheral nerves:                                PR-                              BP-
 Comorbidities:
      Diabetic :Y/N                                 Hypertension:  Y/N                             CAD:  Y/N
     Tuberculosis : Y/ N                                      CKD: Y/N
     Opportunistic infections:    ----------------- ,--------------------,-----------------,-----------------
--
     Any other illness:
alcoholism smoking
 INVESTIGATIONS :     CD 4 COUNT;
Hematology       TC :            DC:     P        L      E      B            HB :         ESR:
   sugar             urea            creatinine              Na          k        Ca
   LFT:                                                    ECG :                                         CXR   :
 CSF analysis (If needed):
 CT BRAIN :
 MRI BRAIN :
 EEG :
P-300 EVALUATION:
WAVE
LATENCY
milli second
AMPLITUDE
micro volt
N1
P2
N2
P3
HIV DEMENTIA SCALE
REGISTRATION  4 WORDS:
ATTENTION  TEST:
ANTISACCADE  [0-4]
PSYCHOMOTOR[0-6]
RECALL               [0-4]
CONSTRUCTION[0-2]
TOTAL SCORE
  TREATMENT :
                        ART:   Y/ N
                        DURATION:
                       ART  DETAILS;
                       OI PROPHYLAXIS:
                       OTHER TREATMENT:
 HIV PATIENTS
S.NO AGE SEX DUR ILL YRS HIV DS  SCORE P3, N1 L ms   P2 L ms   N2 L ms    P3 L ms P-3,Amp micV    CD4+ CT BRAIN MRI BRAIN ART
1 36 1 4 12 111.46 209.38 268.75 350.12 6.82 456 NO NO yes
2 37 2 1 14 82.4 160.4 200.5 312.3 8.4 522 NO NO yes
3 33 1 4 12.5 125 164 240 322.9 3.16 457 NO NO yes
4 35 1 1 13 114.58 171.88 284.38 332.29 2.47 424 NO NO yes
5 38 1 6 12 120.6 224.6 312 442.32 2.34 322 NO NORMAL yes
6 37 1 5 12.5 90.6 170.4 258.6 376.4 6.4 376 NORMAL NO yes
7 42 1 4 14 108.3 166 280.4 304 8.4 606 NO NO yes
8 38 2 1 14 102 160.4 248.4 322.4 5.3 512 NORMAL NO yes
9 41 2 3 11.5 112 170.7 268.6 314 6.3 852 NO NO yes
10 38 1 4 15.5 90.8 168.3 283.5 356.2 3.8 422 NO NO yes
11 43 1 2 14 102.7 156 260.2 342 6.3 511 NO NO yes
12 34 2 7 12 132.4 198.4 286.3 412.8 2.4 254 NO NORMAL yes
13 36 1 6 15 90.6 174.2 223.5 312.6 7.4 867 NO NO yes
14 39 1 2 14.5 88.4 162.4 200.6 316 6.8 765 NO NO yes
15 32 1 2 13 90.4 171.4 244 304 8.2 542 NO NO yes
16 42 1 8 12.5 137.3 174 322 437.8 3.8 322 NO NO yes
17 39 1 7 12 142 200.3 331.4 476.4 2.6 342 NO NORMAL yes
18 32 2 3 14 88.4 150 200.4 306 8.4 744 NO NO yes
19 43 2 6 13.5 126.8 160.8 260.7 340.7 4.4 422 NO NO yes
20 34 1 3 14.5 90.4 173 222.6 352 6.4 480 NO NO yes
21 42 1 4 12.5 100.2 162.4 206.6 322.8 5.4 658 NO NO yes
22 38 2 5 11.5 145 190.4 302.2 390.4 3.2 344 NORMAL NORMAL yes
23 29 1 2 15 92 164.8 212 306.2 9.4 732 NO NO yes
24 39 1 8 12.5 112 178.4 224.6 322.2 6.4 658 NORMAL NORMAL yes
25 36 1 1 15.5 91.4 150 190.4 306.4 10.4 720 NO NO yes
26 33 2 2 13.5 92.6 160.4 188.4 302 7.6 680 NO NO yes
27 52 1 6 12.5 138 190.8 240.6 368 4.4 432 NO NORMAL yes
S.NO AGE SEX DUR ILL YRS HIV DS  SCORE P3, N1 L ms   P2 L ms   N2 L ms    P3 L ms P-3,Amp micV    CD4+ CT BRAIN MRI BRAIN ART
28 35 1 4 15 100.4 168 198 306.4 9.2 603 NO NO yes
29 36 2 5 11.5 122 172.4 212.6 332.4 7.9 687 NO NO yes
30 31 1 3 14.5 88.2 168.8 204 312.3 9.4 723 NO NO yes
31 46 1 5 12 132.4 180.4 238 364.6 4.6 412 NO NO yes
32 32 2 4 15 88.4 174 196.2 306.2 9.8 982 NO NO yes
33 28 1 3 15 90.2 176 242 307.8 10.4 580 NO NO yes
34 34 1 4 14.5 94.4 166.4 202.8 322.4 8.4 564 NO NO yes
35 28 2 3 14.5 98.6 162 188.4 304 9.4 842 NO NO yes
36 39 1 6 12 146.2 212.4 306.2 422 4.4 322 NO NORMAL yes
37 34 1 5 13.5 100.2 162.4 222 308.4 8.2 788 NO NO yes
38 32 2 4 14 108.2 158.4 182.4 310.6 9.4 688 NO NO yes
39 38 1 3 14 112.4 176.4 221.6 322.2 6.4 526 NO NO yes
40 37 1 2 13 98.2 184.2 212 310.4 8.4 634 NO NO yes
41 27 2 3 14 98.4 176.4 232 312.4 9.4 742 NO NO yes
42 46 2 8 12 120.2 202.2 288.6 422.4 5.4 428 NO NO yes
43 36 1 4 14.5 102.6 182.4 204.6 320 9.4 562 NO NO yes
44 32 1 1 15 106.2 172 223.2 298.8 10.2 568 NO NO yes
45 38 2 5 11.5 112 168.8 240.4 388.8 4.4 442 NO NO yes
46 53 1 5 12 132.6 224 288.3 456 3.2 324 NO NORMAL yes
47 35 1 6 13 112.9 168 220.2 318.4 8.8 424 NO NO yes
48 32 2 5 13.5 102 168.4 230.8 322 9.2 568 NO NORMAL yes
49 44 1 7 12 143 202.2 270.1 442.4 3.8 380 NORMAL NO yes
50 37 1 4 13.5 88.8 176 234 311.8 8.6 547 NO NO yes
S.NO AGE SEX DUR ILL YRS HIV DS  SCORE P3, N1 L ms   P2 L ms   N2 L ms    P3 L ms P-3,Amp micV    CD4+ CT BRAIN MRI BRAIN ART
51 35 1 15.5 90.4 160.4 202.4 312.6 12.4
52 38 1 14 94 168.2 212 316.3 9.4
53 26 2 14 92.4 174.3 200.8 328.2 8.4
54 36 2 15 96.3 160.8 206 312.2 9.8
55 38 1 13.5 88.4 158.9 198 321 12.6
56 24 2 15.5 94 176.4 221.4 332 10.4
57 56 1 13 94.2 198.4 223.4 332.4 8.4
58 32 1 15 92 162.4 200.7 310 11.2
59 39 2 13.5 89.3 182.8 231 312 10.3
60 48 1 14 98.8 162.1 241.6 322 8.4
61 44 1 14.5 92.4 176 232.2 308.2 12.4
62 35 1 13 89.4 174.2 223.4 320.2 10.4
63 32 2 14 92.8 182.2 212.8 312.7 9.8
64 38 2 13.5 104.7 188 267.5 345.2 9
65 33 1 15.5 100.2 186.6 258.9 332 10.5
66 46 2 14 88 167.4 210.4 316.4 9.4
67 31 1 15.5 92 162.6 210.4 312 12.4
68 48 1 16 96.4 170.4 223.4 318.4 10.4
69 38 2 15 112.4 190.4 254 324.4 9.3
70 34 2 16 92.4 167.4 232.4 308 12.4
71 37 1 15.5 100.6 182.3 244.4 312.8 13.8
72 31 1 14.5 88.3 173.4 242.4 320.4 12.6
73 43 1 15 92.4 174.2 258 310.4 11.6
74 42 2 13.5 92 164.4 245.4 322.6 9.4
75 44 1 14 102.4 188.4 267.8 333 8.8
76 32 1 14 98.4 176.4 270.3 340.4 9.4
77 45 2 13 92 160.6 240.2 312.8 10.4
CONTROLS
S.NO AGE SEX DUR ILL YRS HIV DS  SCORE P3, N1 L ms   P2 L ms   N2 L ms    P3 L ms P-3,Amp micV    CD4+ CT BRAIN MRI BRAIN ART
78 33 1 16 87.2 168.4 254 308.9 8.6
79 35 2 15 98.2 182.7 245.4 312.8 10.4
80 52 1 14 121 196.4 274.8 356.3 7.4
81 39 2 16 98 167.3 256 322.4 8.9
82 28 2 15.5 92 172.4 248.4 314.8 9.8
83 56 1 13 112.4 158.5 287.2 332.4 8.4
84 25 2 14.5 110.3 184.3 267 312.6 12.4
85 44 2 14 100.2 172.4 250.3 326 11.8
86 35 1 13.5 116.4 167.3 278.3 345.3 9.8
87 39 1 14 121.2 182 290.4 345.7 8.2
88 36 2 15.5 89.4 167 200.4 308.4 13.4
89 42 2 14.5 93.8 158 212.4 309.7 12.8
90 28 1 14 90.6 162.4 222.2 322 13.8
91 33 2 15 89.4 173.6 200.4 322.5 12.8
92 38 1 14.5 112.4 168.4 228.8 356.3 7.8
93 48 1 14 116.3 172.2 254.4 367.8 8.3
94 37 2 11.5 92.9 172.4 224.4 316.8 9
95 35 1 15 96.3 158 245.1 312 10.3
96 33 1 15.5 90.4 169.4 232 322.8 11.2
97 37 2 16 88.7 174.6 226.2 309.4 10.4
98 56 1 13.5 134 162.4 284.8 360.4 7.8
99 42 1 13.5 117.2 177.8 274 356.8 6.7
100 47 1 13 120.4 188.4 268.4 332.8 7.8
101 33 1 15 98.4 178 200.3 323 13.2
102 36 2 12 99 167.3 212.4 300.9 10.4
103 25 1 16 102.7 188.2 243 312.9 12.3
104 34 1 14.5 109.3 167 284 342.2 10.2
105 38 2 14 103.7 165.4 265.4 332 9.8
106 33 1 13 112.4 178.4 275.2 345.8 8.2
S.NO AGE SEX DUR ILL YRS HIV DS  SCORE P3, N1 L ms   P2 L ms   N2 L ms    P3 L ms P-3,Amp micV    CD4+ CT BRAIN MRI BRAIN ART
107 54 1 14 120.8 188.4 290 367.4 6.7
108 31 2 16 89.4 182 200.4 322 9.6
109 38 1 16 90.4 176.2 221 335.9 10.2
110 35 1 14 108.4 168.4 234.6 344.2 7.4
sex: 1-male HIV DS SCORE-HIV Dementia Scale score Amp-Amplitude  ART-Anti Retroviral Therapy
         2-female L-Latency
HIV-Human Immuno Deficiency Virus ms-milliseconds
DUR ILL YRS-Duration of illness in years micV-Microvolts
